Earnings Releases·Nov 3, 2026, 4:05 PM ET

RxSight, Inc. — Third Quarter 2026 Earnings Summary

Total revenue declined 19% year-over-year to $24.6 million, while the net loss widened to $(16.2) million ($0.39 per share) from $(9.8) million ($0.24 per share) in the prior-year period.
Gross margin contracted to 73.6% from 79.9% due to increased inventory reserves and higher costs for LAL and LDD, despite favorable product mix.
The company recorded a $50.0 million refund liability and received $60 million from the Alcon collaboration, bringing total cash, equivalents, and short-term investments to $254.7 million.
Strategic initiatives include a significant organizational restructuring, doubling the sales force, and appointing new commercial leadership to address competitive pressures.
Year-to-date 2026 revenue was $89.2 million (down from $101.9 million), with an adjusted net loss of $(21.2) million compared to $(6.0) million in 2025.